Skip to main content

Non-Viral, Non-Integrating DNA Vectors for the Safe and Efficient Engineering of Primary Human Cells


Kurzfassung

This technology utilizes a novel DNA vector platform for the safe and efficient generation of genetically engineered cells. This DNA vector system contains no viral components and comprises only clinically approved sequences, which makes it ideal for applications for human therapy such as immuno- and stem-cell therapy.


Hintergrund

The system is based on an S/MAR element. It does not integrate into target cells’ genomes and it replicates autonomously and extrachromosomally in the nucleus of all dividing eukaryotic cells.

Convincing preclinical data has shown that the system produces stably transfected cells in vitro and in vivo in which the expression of transgenes is persistently sustained at high levels without decline in primary human T-Cells, stem cells and cancer cell lines. We have demonstrated that our DNA Vectors can genetically modify T-Cells to express transgenic Chimeric Antigen Receptors and T-Cell Receptors without adversely affecting their viability. Most importantly we demonstrate that these modified cells can efficiently target and kill human cancer cells in vitro and in mouse models as effectively as currently used clinically applied viral vectors.   


Lösung

  • Safe, persistent and efficient genetic modification
  • Only clinically approved components
  • Applications include immunotherapy, stem cell therapy, and biotechnology

Anwendungsbereiche

The applications span all areas of genetic engineering. In particular this system is a safer technology for the introduction of T-Cell receptors or Chimeric Antigen Receptor into naive Human T-Cells that can be used for autologous immunotherapy.

There are currently over 300 clinical trials in this area. In the majority of these trials the genetic modification of the cells is achieved using a randomly integrating systems such as lentivirus or transposons. Immunogenicity and the risk of genotoxicity associated with their random genomic integration still represent a fundamental limitation of these systems.

Our technology, on the other hand, avoids the risk of integrative mutagenesis and the potential for the reactivation of endogenous viruses or transposons. Additionally, no other vector of this class is capable of providing the efficiency, cost-effectiveness and persistence of transgene expression in dividing primary cells of this vector system. 


Deutsches Krebsforschungszentrum DKFZ

Svetlana Semykina
06221-42-2953
s.semykina@dkfz.de
www.dkfz.de
Adresse
Im Neuenheimer Feld 280
69120 Heidelberg



Entwicklungsstand

Präklinik


Stichworte

Therapeutics, Research Tools

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr